Cyclooxygenase-2–specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
A Whelton, JG Fort, JA Puma… - American journal of …, 2001 - journals.lww.com
A Whelton, JG Fort, JA Puma, D Normandin, AE Bello, KM Verburg, Success VI Study Group
American journal of therapeutics, 2001•journals.lww.comBackground Arthritis and hypertension are common comorbid conditions affecting elderly
adults. Use of nonsteroidal anti-inflammatory drugs in patients treated with antihypertensive
medication can lead to destabilization of blood pressure control and other cardiorenal
events. The potential for similar interactions with cyclooxygenase-2–specific inhibitors has
not been fully explored. The authors evaluated the cardiorenal safety of two new
cyclooxygenase-2–specific inhibitors, celecoxib and rofecoxib. Methods This study was a 6 …
adults. Use of nonsteroidal anti-inflammatory drugs in patients treated with antihypertensive
medication can lead to destabilization of blood pressure control and other cardiorenal
events. The potential for similar interactions with cyclooxygenase-2–specific inhibitors has
not been fully explored. The authors evaluated the cardiorenal safety of two new
cyclooxygenase-2–specific inhibitors, celecoxib and rofecoxib. Methods This study was a 6 …
Abstract
Background
Arthritis and hypertension are common comorbid conditions affecting elderly adults. Use of nonsteroidal anti-inflammatory drugs in patients treated with antihypertensive medication can lead to destabilization of blood pressure control and other cardiorenal events. The potential for similar interactions with cyclooxygenase-2–specific inhibitors has not been fully explored. The authors evaluated the cardiorenal safety of two new cyclooxygenase-2–specific inhibitors, celecoxib and rofecoxib.
Methods
This study was a 6-week, randomized, parallel-group, double-blind trial in patients with osteoarthritis who were≥ 65 years of age and were taking antihypertensive agents. Patients received once-daily celecoxib 200 mg or rofecoxib 25 mg. The primary endpoints were the development of edema, changes in systolic blood pressure, and changes in diastolic blood pressure as measured at any time point in the study. Measurements occurred at baseline and after 1, 2, and 6 weeks of treatment.
Lippincott Williams & Wilkins